Chronic Myeloid Leukemia Coverage From Every Angle

Recent News

Study Finds Novel Compound Reduces Survival of Imatinib-Resistant CML Cells
Translational CML Study of Nilotinib Versus Imatinib: Focus on Adipocyte Toxicity
Does Imatinib Affect Bone Marrow Morphology in Chronic Myeloid Leukemia?
Achievement of Treatment-Free Remission in CML Influenced by Transcript Variant
MD Anderson–Led Research Initiative Seeks New Agents for CML and Other Leukemias
Novel Genetic Biomarker for Predicting Response to Imatinib Therapy for CML
Feasibility of Stopping Lifelong Tyrosine Kinase Inhibitor Therapy in CML
Interim TIGER Trial Results With Nilotinib Plus Interferon in CML
Controlling Graft-vs-Host Disease in Older Patients After Stem Cell Transplantation
Use of Risk Stratification Scores in Elderly Patients With CML
First-Line Nilotinib Treatment In Newly Diagnosed CML
TKI Resistance and Compound BCR-ABL1 Kinase Domain Mutations in Leukemia
Novel Therapeutic Strategy May Improve Treatment Efficacy Against Leukemia
ASH 2018: 5-Year Analysis of Imatinib vs. Dasatinib in Newly Diagnosed Chronic Phase CML
ASH 2018: Making the Decision to Switch to Dasatinib From Imatinib in CML
ASH 2018: Intermittent TKI Therapy in Elderly Patients With CML
ASH 2018: Might Asciminib Become a New Treatment Option in CML?
ASH 2018: Is Generic Imatinib as Effective as Its Brand Counterpart in Chronic Phase CML?
ASH 2018: Cardiovascular Events Associated With Ponatinib Treatment of CML
Rare Case of CML After Transplantation in Patient With Multiple Myeloma
FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease
ESMO 2018: Bosutinib vs. Imatinib in Indian and Non-Indian Patients With CML
ESMO 2018: Nurse-Led Approach to Monitor Use of Oral Treatments in CML
Bone Morphogenic Protein Pathway Essential for CML Cells
ESMO 2018: Compound Mutations and Response to Therapy With Tyrosine Kinase Inhibitors
FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies
Case Report of Elevated Intracranial Pressure in Patient With CML
Cancer Research UK Grants Funding to University of Glasgow for CML Research
Novel Approach to Restoring Beneficial Gut Bacteria After HCT
Nilotinib and Dasatinib Go Head-to-Head in Retrospective CML Study

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.